Lipids and lipoprotein fractions after cyclopenthiazide and oxprenolol: a double-blind crossover study.
A double-blind crossover study was carried out to investigate the effects of cyclopenthiazide and oxprenolol on blood lipids in 20 previously untreated patients with mild to moderate hypertension. After a 4-week placebo period, patients received at random either 8-weeks' treatment with the two drugs followed by 8 weeks on cyclopenthiazide alone, or the reversed sequence. Daily doses were 160 mg slow-release oxprenolol and/or 0.25 mg cyclopenthiazide during the first 4 weeks of each treatment period, after which the dosage was doubled. Data from 13 patients who completed the trial showed no significant changes in the blood levels of triglycerides, total cholesterol or LDL and HDL cholesterol fractions. These findings are discussed in relation to published studies on the effects of other beta-blockers on blood lipids.
D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D003518:Cyclopenthiazide / Q000627:therapeutic use*; D004232:Diuretics; D004311:Double-Blind Method; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D010096:Oxprenolol / Q000627:therapeutic use*; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D004232:Diuretics; D008055:Lipids; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D049993:Sodium Chloride Symporter Inhibitors; D014280:Triglycerides; D010096:Oxprenolol; D002784:Cholesterol; D003518:Cyclopenthiazide